[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins

Amylin and gastric emptying: overlapping mechanisms with incretins — setting out what I have, and where I think it stops being reliable.

A question about Amylin and gastric emptying that I think has a definite answer, unlike most of what I ask here.

I have the reasoning below and I am fairly confident about the direction. I am not confident about the size, and the size is what the decision turns on.

Native amylin has awkward physical properties — it aggregates readily, which is why a stable analogue is a pharmaceutical achievement rather than a formulation detail.

If the premise is wrong, everything after it is decoration.

The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.

Correct me on the arithmetic if it is wrong; I would rather know.

Bookmarking this. I will come back when I have something worth adding.

Everything in post #3 holds. The case it does not cover is the one I have.

I keep a log for Amylin and gastric emptying specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.

What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials.

For what it is worth, the same held on the two occasions I checked.

Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.

Adding it because I spent an afternoon working it out and nobody should have to twice.

Answering the question post #7 raises rather than the one it answers.

On Amylin and gastric emptying, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.

If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.

The arithmetic in post #7 is right; the assumption feeding it is the part to check.

I would rather this thread reach "we do not know" about Amylin and gastric emptying than reach a confident answer that nobody can support when asked.

On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.

Where I part company with post #10, and it is a narrow parting.

The version of Amylin and gastric emptying that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.

Adding the measurement that post #12 says would settle it.

Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.

I have left out the parts I could not verify.

Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.

Reading it again, the caveat matters more than the finding.